92-C-0137 A trial of carboxypeptidase- G2 (CPDG2) for the management of patients with intrathecal methotrexate over-dose.

Principal Investigator: Dr. Brigitte Widemann

00-C-0070: A Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients with Refractory Leukemia or Lymphoma

Principal Investigator: Dr. Frank Balis

01-C-0091: A Phase I Trial and Pharmacokinetic Study of XR9576, a P-Glycoprotein Inhibitor, in Combination with Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients with Refractory Solid Tumors Including Brain Tumors

Principal Investigator: Dr. Frank Balis

00-C-0105: A Phase I Trial and Pharmacokinetic Study of Temozolomide and O6Benzylguanine in Childhood Solid Tumors

Principal Investigator: Dr. Frank Balis

90-C-0095: Phase I Study of Intrathecal Mafosfamide

Principal Investigator: Dr. Frank Balis

01-C-0196: A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients with Refractory Leukemias

Principal Investigator: Dr. Frank Balis

02-C-0031: A Phase I trial and pharmacokinetic study of BMS-247550 (NSC 710428), an epothilone B analog, in pediatric patients with Refractory solid tumors

Principal Investigator: Dr. Frank Balis

02-C-0141 A Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Biovailable Tubulin Binding Agent, in Pediatric Patients with Refractory Solid Tumors

Principal Investigator: Dr. Frank Balis

04-C-0079: Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas

Principal Investigator: Alan Wayne

04-C-0168: Pediatric Phase I Trial of LMB2 for Refractory CD25-Positive Leukemias and Lymphomas

Principal Investigator: Alan Wayne

Also see Phase 2 Clinical Trials
Pharmacology and Experimental Therapeutics Section

Last Updated::October 3, 2006

NCI Home Page|| NIH Home Page

© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute